TITLE: latest news on mots-c benefits and fda approval EXCERPT: MOTS-c is a peptide studied for metabolism and exercise capacity. TAGS: mots-c, peptide, fda approval
Key takeaways
- MOTS-c is a research-stage peptide with potential benefits for metabolism and exercise capacity.
- It is not FDA-approved and its nomination for FDA compounding was withdrawn in April 2026.
- An FDA advisory committee voted to recommend adding it to the 503A bulks list, but a final decision is pending.
- Human data on MOTS-c is limited, with most studies conducted in mice.
Recent studies have explored the potential benefits of MOTS-c for metabolism and exercise capacity. While most research has been conducted in mice, human studies are starting to emerge. MOTS-c has been shown to improve insulin sensitivity, protect against diet-induced obesity, and boost exercise capacity in animal models 123. However, its effects in humans are not yet fully understood.
MOTS-c's potential benefits
{{mots-c}} MOTS-c has been linked to improved mitochondrial function and metabolic regulation 4. It is thought to activate AMPK and shift cellular metabolism, mimicking some exercise effects. However, more research is needed to confirm its potential benefits in humans. A Phase 2a study is currently recruiting participants to evaluate the effects of MOTS-c on insulin sensitivity in adults with prediabetes and overweight/obesity 5.
FDA approval status
The FDA has not approved MOTS-c for any use. Its nomination for FDA compounding was withdrawn in April 2026 6. However, an FDA advisory committee voted 7-5 to recommend adding it to the 503A bulks list in July 2026 6. This recommendation is not a guarantee of approval, and the FDA's final decision is pending.
Comparison to other peptides
While MOTS-c is a promising research peptide, it is not the only one being studied for its potential benefits. Other peptides, such as Semaglutide, are also being investigated for their effects on metabolism and weight loss. A comparison of these peptides is shown in the table below:
| What it is | FDA status | Evidence (1-5) | Half-life | Banned in sport |
|---|---|---|---|---|
| MOTS-c | Not FDA-approved | 2 | Short | Yes |
The bottom line
MOTS-c is a research-stage peptide with potential benefits for metabolism and exercise capacity. While its effects in humans are not yet fully understood, ongoing studies may provide more insight into its potential uses. As with any research peptide, it is essential to consult with a healthcare professional before using MOTS-c or any other peptide.
This is educational information, not medical advice.
Sources
- MOTS-c in sepsis-induced cardiomyopathy: Mechanisms and translational potential — European journal of pharmacology, 2026/10/15
- MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation — Autophagy, 2026/10/01
- MOTS-c mediates remote ischemic preconditioning-induced protection against lung ischemia-reperfusion injury via NRF2-dependent mitochondrial biogenesis — Chinese medical journal, 2026/09/21
- Mitokines as bioenergetic stress signals in cardiovascular disease: mitochondrial communication, endocrine adaptation, and translational implications — Journal of bioenergetics and biomembranes, 2026/09/14
- MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity — RECRUITING, PHASE2, 2026-04-01
- Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List — Health and Human Services Department, Food and Drug Administration, 2026-04-16